PREP

This activity is supported by an educational grant from Janssen Therapeutics, division of Janssen Products, LP.

Top news of the week from Pharmacy Times. 
 

Less than 10% of the people who should be taking pre-exposure prophylaxis for HIV are taking the medications. 

 

Insurance companies are currently investigating the option of modifying which medications they will cover for HIV pre-exposure prophylaxis (PrEP) therapy, with broad implications for patient access.

Learn how retail or specialty pharmacy distribution can affect access to these important drugs.

Although the use of preexposure prophylaxis against HIV has increased across the United States in recent years, the rise in costs across the health care system has yet to be fully catalogued.

Men at particular risk for HIV are very likely to consistently take preventative medication during vacations when their odds of contracting the virus are higher, according to a study conducted by researchers at the University of Pittsburgh.

The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) study has played a key role in helping the health care industry look closer at the disproportionate risk of comorbidities, such as chronic liver and kidney disease, physical function impairment and frailty, premature reproductive aging, and cancer in patients with HIV.

Regional and state access assistance, improved research and collaboration, and individualized options for patients are key factors in adherence to PrEP.

The new report intends to change the practices in the HIV/coinfections research community so that women, providers, and policy makers can make evidence-based decisions regarding the use of medications during pregnancy.

Event-driven PrEP is initiated 2-24 hours ahead of sexual activity, but the most common method of HIV PrEP is a daily oral pill.

Small, automated financial incentives improved retention in care and viral suppression among adults with HIV starting antiretroviral therapy.